adj	Adjuvant
APBI	Accelerated hypofractionated partial breast irradiation
BC	Breast cancer
BCS	Breast-conserving surgery
CCL	Chemokine ligands
CHT	Chemotherapy
CRT	Combined chemo/radiotherapy
CSF2	Colony-stimulating factor 2 (granulocyte-macrophage)
CTGF	Connective tissue growth factor
CTR	Controls
CXCL	Chemokine (C-X-C motif) ligand
CYFRA 21-1	Cytokeratin 21-1 fragment
d	Dose/fraction
DAMP	Danger-associated molecular pattern
EGF	Epidermal grow factor
ER	Estrogen
FOXP3	Forkhead box P3, also known as scurfin
frs	Fractions
GES	Gene-expression signature
Gy	Gray
HC	Healthy control
Her-2	Human epidermal growth factor receptor-2
HT	Hormonal therapy
IBAPBI	Intracavitary brachytherapy accelerated hypofractionated partial breast irradiation
IFNA2	Interferon, alpha 2
IFNβ	Interferon beta
IFN-γ	Interferon gamma
IL	Interleukin
IL-1RA	Interleukin-1 receptor antagonist
IL5RA	Interleukin 5 receptor, alpha
IL10RB	Interleukin 10 receptor, beta
IORT	Intraoperative radiotherapy
LH-RH	Luteinizing hormone releasing hormone
LPS	Lipopolysaccharide
MCP-1	Monocyte chemoattractant protein-1
MFS	Metastasis-free survival
MIC-1/GDF15	Macrophage inhibitory cytokine 1/growth differentiation factor 15
NA	Not available
OPG	Osteoprotegerin
OS	Overall survival
OSM	Oncostatin M
PDGF-AB	Platelet-derived growth factor anti-body
PFS	Progression-free survival
PR	Progesteron
Pts	Patients
RA	Retinoic acid
RANK	Receptor activator of nuclear factor kappa B
RIF	Radiation-induced fibrosis
RSI	Radiosensitivity index
RT	Radiotherapy
S	Surgery
SBRT	Stereotactic body radiation therapy
SCC-Ag	Squamous cell cancer antigen
SN	Supernatant
TD	Total dose
TGF-α	Transforming growth factor alpha
TGF-β1(b1)	Transforming growth factor beta-1
TNBCs	Triple-negative breast cancers
TNF-α	Tumor necrosis factor-alpha
TNFSF13	Tumor necrosis factor (ligand) superfamily member 13
VEGF	Vascular endothelial growth factor
WF	Wound fluid
y	Years